@graokane

Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦

researchgate.net/profile/Grainne-Okane
Joined August 2013
  • Tweets970
  • Following634
  • Followers2.1K
185Media
OPTIMUM rand ph2 adv #BTC ➡️dx control on plat- olaparib v olaparib/durva ➡️somatic/ germline DDR but wide range genes ➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm) ❎no diff 6mth PFS ❎1yr OS rate 64 v76% ❗️we must define true HRD in trials & understand TME @myESMO #ESMO26 @OncoAlert
7
6
386
Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE ➡️mPFS 14.6 v 10.2 HR 0.7 ➡️ORR 71 v 49% by mRECIST ❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx ❎much higher gd3/4 TRAEs 71%v31% ➡️❗️1/3 BCLCA ➡️Role combo unclear consistent -ve OS @myESMO #ESMO26 @OncoAlert
8
7
420
🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1) ➡️two cohorts n=60 #PDAC ➡️safety- mainly haem, none precluded surgery ➡️ORR 63% & 87%;MPR in 17% ➡️R0 resection rate 100% ✅6 mth EFS rate 87% & 96% ➡️100% ⬇️CA19.9; OS pending @myESMO #ESMO26 @OncoAlert
11
10
521
INCB161734 KRASG12D (ON/OFF) + GnP or mFFX; updated ph1, n=53 ➡️mostly GI toxicity,dose intensity 85% with GnP & 77%mFFX ✅ORR 69%, DCR 96% GnP ✅ORR 89%, DCR 100% mFFX ➡️6 mth PFS rates 80% & 90% ⭐️impressive & can combine mFFX ✅DAWN-303 ph3 ongoing @myESMO #ESMO26 @OncoAlert
13
20
684
Intrahepatics doing best with GBC and extra hepatic OS HR not as favourable; GBC definitely different biology, with HR similar to TOPAZ in this primary site; more research needed @CharityAMMF @PrecisionBTCnet @curecc
Grainne O'Kane
@graokaneOct 25
🔥HARMONi-GI1 ph3 advanced #BTC ➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim ✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths ✅mOS 14.9 v12.1mths HR0.75 ➡️AE rate high in both Control arm OS represents❗️VEGF in BTC ⭐️ looks promising @myESMO #ESMO26 @OncoAlert
3
9
434
🔥HARMONi-GI1 ph3 advanced #BTC ➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim ✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths ✅mOS 14.9 v12.1mths HR0.75 ➡️AE rate high in both Control arm OS represents❗️VEGF in BTC ⭐️ looks promising @myESMO #ESMO26 @OncoAlert
13
2
18
2,543
Masterful talk @BasGrootKoerkam on localised #PDAC & #BTC 🔑points👇 ➡️PDAC staging requires anatomy/biology/clinical ass ➡️?older patients benefit NAC ➡️hilar obs➡️perc stenting TESLA ➡️high risk iCCA consider NAC ➡️LRT & Liver tx evolving in iCCA @myESMO #ESMO26 @OncoAlert
16
1
40
4,030
GFH276 pan-RAS (ON) molecular glue ➡️ph1/1b data; n=73 PDAC ,5-320mg ➡️no . prior lines tx =2 ➡️ORR 41% in #PDAC, @ 40-160mg, small nos with prior RASi ➡️Rash most common AE As many trials move quickly to 1st line, how will we sequence?? @myESMO #ESMO26 @OncoAlert
5
19
2
38
2,872
Grainne O'Kane retweeted
Lorenza Rimassa@LorenzaRimassaOct 24
Today I had the honor to discuss two important abstracts of novel treatment approaches for patients with #HCC across different stages and settings at #ESMO26. Not yet in clinical practice, but clinically relevant results. #ESMOAmbassadors @myESMO @HUNIMED @HumanitasMilano
1
12
25
1,249
🔥Promising #HCC BGB-B2033 ➡️GPC3 x 4-1BB bispecific ph1/2 more mature data ➡️dose escalation/optimisation activity across all: 2/3rd >2 prior lines ORR ~36% ➡️450mg selected R2PD; very favourable toxicity ➡️Phase 3 GroundBBreaker 301 due to open @myESMO #ESMO26 @OncoAlert
1
14
20
1,199
Much anticipated ACTICCA-1 ➡️adj cis/gem v cape #BTC ➡️mod ITT n=591 ➡️no diff in DFS at 24mth 52% v 44% RMST at 3 yrs ⬆️DFS by 2.6mth ➡️28% iCCA -no maj subgroup diff ➡️mOS 58.1 v 48.2 p=0.1 ❎No change to std ?an option, NB need as backbone 1st line! @myESMO @OncoAlert #ESMO26
2
22
1
28
1,689
Paclitaxel +\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️ORR 17.1 v5.3%; DCR 62 v 37% ➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover ➡️OS not sig but nb crossover @myESMO #ESMO26 @OncoAlert
9
12
712
MASTERPLAN randomised ph2 ➡️chemo(90% mFFX) +\-SBRT localised #PDAC ➡️included potentially operable high risk /BR &LAPC not operable ➡️primary endpoint 12mth LRR :20% v 52% ➡️more R0 resections with SBRT ➡️mPFS 11.9 v6.3mth; mOS 22 v 14mth @myesmo #ESMO26 @oncoalert
3
14
19
1,145
And we are 🚀 #ESMO26 🔝GI abstracts! 👇
OncoAlert
@OncoAlertOct 22
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬 From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇 #GICancer #CRCSM @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi , @GillSharlene
4
6
401
AMPLIFY-7P randomised ph2 ✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile ➡️curative intent & no recurrence <6mth #PDAC ✅T cell responses,primary endpt-ve ➡️benefit in ctDNA-ve& no rads? ➡️DFS @6mth benefit of 14% p=0.056 ✅ph3 planned @myESMO @OncoAlert #ESMO26
1
14
11
666
#LBA82 subgroup analysis RASolute 302 #PDAC ➡️HR for OS across subtypes 0.32-0.46 ➡️G12R 0.61 (0.29-1.30) ➡️RAS WT numbers small (3%) but still OS benefit! 🤔perhaps ORR and mPFS not as pronounced in these populations! ✅std second line treatment @myESMO #ESMO26 @OncoAlert
1
15
1
20
1,414
Load more